NDAORALTABLET
Approved
Oct 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
26
Data completeness
3/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOTRIENT (pazopanib hydrochloride) is an oral small-molecule multi-tyrosine kinase inhibitor approved by FDA on October 19, 2009. It blocks multiple receptor pathways including VEGFR, PDGFR, FGFR, and Kit, thereby inhibiting tumor angiogenesis and cell proliferation. VOTRIENT is indicated for renal cell carcinoma, thyroid cancer, pancreatic neuroendocrine tumors, soft tissue sarcoma, and breast cancer. It represents a foundational vascular-targeting therapy in oncology, though it now faces significant competition from newer agents with improved efficacy and tolerability profiles.
$0.1BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (26)
HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
Started Apr 2022
47 enrolled
Advanced Soft-tissue SarcomaMetastatic Soft-tissue Sarcoma
Pazopanib Vs. Pazopanib Plus Gemcitabine
Started Oct 2019
58 enrolled
Leiomyosarcoma or Carcinosarcoma
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Started Feb 2018
5 enrolled
Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8+2 more
SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
Started Jan 2017
0Gastrointestinal Stromal Tumors
Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer
Started Jun 2015
118 enrolled
Ovarian Cancer
Worked on VOTRIENT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.